Investigational drug · Phase 2
GAL-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Geographic Atrophy of the Macula.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "GAL-101"
First trial start
2025
Jan 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GAL-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Geographic Atrophy of the Macula
Approved drugs for the same conditions: Geographic atrophy
Largest trials
Live from ClinicalTrials.gov: studies naming "GAL-101" as an intervention, largest first.
- A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMDPivotal-lookingRecruiting
Galimedix Therapeutics IncIndustry
NCT06659549 · 110 participants (planned) · Start Jan 10, 2025 · Primary completion Mar 30, 2028
Drug: GAL-101; Placebo · For: Geographic Atrophy of the Macula
Sites: Beverly Hills, California; Walnut Creek, California; Hagerstown, Maryland · 24 sites in all
- A 28-Day Study of GAL-101 in Participants With Mild to Moderate Alzheimer's DiseasePivotal-lookingNot yet recruiting
Galimedix Therapeutics IncIndustry
NCT07789873 · 100 participants (planned) · Start Feb 28, 2027 · Primary completion Apr 30, 2028
Drug: GAL-101 Salt; Placebo · For: Mild to Moderate Alzheimer's Disease
Galimedix Therapeutics IncIndustry
NCT07780604 · 92 participants · Start Nov 18, 2024 · Primary completion Sep 18, 2025
Drug: Uncoated GAL-101 Salt 1170 mg; Placebo and 6 more · For: Healthy Adult Participants
Sites: Bloemfontein, South Africa
Newest research
PubMed records naming it or its code names, newest first.
Also in development for Geographic Atrophy of the Macula
- AVD-104Phase 21 trial
Aviceda Therapeutics, Inc. · Geographic Atrophy of the Macula, Macular Degeneration
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.